Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2021 Filed Jan 14, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-003491 · doc4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 5,128 | $63.10 | $323,576.80 |
DisclosureSEC source: 0001209191-21-003491 · doc4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.887 to 63.73, inclusive. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 9,872 | $62.47 | $616,703.84 |
DisclosureSEC source: 0001209191-21-003491 · doc4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,128 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.887 to 62.88, inclusive. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-003491 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 75,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-003492 · doc4.xml · derivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,000 Underlying: Common Stock · 75,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 1,200 | $63.73 | $76,476.00 |
DisclosureSEC source: 0001209191-21-003492 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.71 to 63.73, inclusive. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 33,827 | $62.96 | $2,129,747.92 |
DisclosureSEC source: 0001209191-21-003492 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.66 to 63.65, inclusive. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 39,973 | $62.25 | $2,488,319.25 |
DisclosureSEC source: 0001209191-21-003492 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,027 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.62 to 62.581, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 75,000 | $6.32 | $474,000.00 |
DisclosureSEC source: 0001209191-21-003492 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| January 11, 2021 Filed Jan 14, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-003491 · doc4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 11, 2021 Filed Jan 14, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 9,756 | $61.74 | $602,335.44 |
DisclosureSEC source: 0001209191-21-003491 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.255 to 62.11, inclusive. Read SEC document |
| January 11, 2021 Filed Jan 14, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 2,544 | $60.68 | $154,369.92 |
DisclosureSEC source: 0001209191-21-003491 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,756 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.16 to 60.99, inclusive. Read SEC document |
| January 11, 2021 Filed Jan 14, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 2,700 | $59.62 | $160,974.00 |
DisclosureSEC source: 0001209191-21-003491 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.10 to 59.76, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 11, 2021 Filed Jan 14, 2021 01:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-003491 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-003150 · doc4.xml · derivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 4,944 | $61.35 | $303,314.40 |
DisclosureSEC source: 0001209191-21-003150 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.22 to 61.59, inclusive. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 6,186 | $60.44 | $373,881.84 |
DisclosureSEC source: 0001209191-21-003150 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,944 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.20 to 60.99, inclusive. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 2,213 | $59.70 | $132,116.10 |
DisclosureSEC source: 0001209191-21-003150 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,130 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.20 to 60.19, inclusive. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 1,657 | $58.82 | $97,464.74 |
DisclosureSEC source: 0001209191-21-003150 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,343 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.17 to 59.10, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 02:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-003150 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-002617 · doc4.xml · derivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 15,000 | $57.30 | $859,500.00 |
DisclosureSEC source: 0001209191-21-002617 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.78 to 57.68, inclusive. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-002617 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-002617 · doc4.xml · derivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 808 | $55.45 | $44,803.60 |
DisclosureSEC source: 0001209191-21-002617 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.35 to 55.47, inclusive. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 14,192 | $54.86 | $778,573.12 |
DisclosureSEC source: 0001209191-21-002617 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 808 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $54.34 to 55.33, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-002617 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 05, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-002618 · doc4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 05, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 363 | $56.56 | $20,531.28 |
DisclosureSEC source: 0001209191-21-002618 · doc4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 05, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 14,637 | $55.98 | $819,379.26 |
DisclosureSEC source: 0001209191-21-002618 · doc4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.395 to 56.31, inclusive. Read SEC document |
| January 05, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001209191-21-002618 · doc4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock (Right to Buy) · Derivative | 1,563 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001209191-21-002378 · doc4.xml · derivative · entry 10 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 1,563 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F7 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-002378 · doc4.xml · derivative · entry 9 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,688 Underlying: Common Stock · 2,604 shares Expires 2028-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,604 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-002378 · doc4.xml · derivative · entry 8 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,042 Underlying: Common Stock · 2,604 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 267 | $59.46 | $15,875.82 |
DisclosureSEC source: 0001209191-21-002378 · doc4.xml · nonDerivative · entry 7 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 495 | $58.63 | $29,021.85 |
DisclosureSEC source: 0001209191-21-002378 · doc4.xml · nonDerivative · entry 6 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.395 to 59.27, inclusive. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 3,800 | $57.82 | $219,716.00 |
DisclosureSEC source: 0001209191-21-002378 · doc4.xml · nonDerivative · entry 5 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 762 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.27 to 58.18, inclusive. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 2,209 | $56.12 | $123,969.08 |
DisclosureSEC source: 0001209191-21-002378 · doc4.xml · nonDerivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,562 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.87 to 56.61, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 1,563 | $7.27 | $11,363.01 |
DisclosureSEC source: 0001209191-21-002378 · doc4.xml · nonDerivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 2,604 | $6.55 | $17,056.20 |
DisclosureSEC source: 0001209191-21-002378 · doc4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionCommon Stock | 2,604 | $6.55 | $17,056.20 |
DisclosureSEC source: 0001209191-21-002378 · doc4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
DOBMEIER ERICDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-002379 · doc4.xml · derivative · entry 6 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 10,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
DOBMEIER ERICDirector
|
SaleCommon Stock | 400 | $59.46 | $23,784.00 |
DisclosureSEC source: 0001209191-21-002379 · doc4.xml · nonDerivative · entry 5 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
DOBMEIER ERICDirector
|
SaleCommon Stock | 592 | $58.67 | $34,732.64 |
DisclosureSEC source: 0001209191-21-002379 · doc4.xml · nonDerivative · entry 4 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.395 to 59.27, inclusive. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
DOBMEIER ERICDirector
|
SaleCommon Stock | 5,725 | $57.76 | $330,676.00 |
DisclosureSEC source: 0001209191-21-002379 · doc4.xml · nonDerivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 992 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.27 to 58.18, inclusive. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
DOBMEIER ERICDirector
|
SaleCommon Stock | 3,283 | $56.10 | $184,176.30 |
DisclosureSEC source: 0001209191-21-002379 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,717 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.67 to 56.61, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:00 UTC |
DOBMEIER ERICDirector
|
Exercise / conversionCommon Stock | 10,000 | $6.32 | $63,200.00 |
DisclosureSEC source: 0001209191-21-002379 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020. Read SEC document |
| January 04, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-002618 · doc4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 04, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 709 | $59.40 | $42,114.60 |
DisclosureSEC source: 0001209191-21-002618 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.27 to 59.46, inclusive. Read SEC document |
| January 04, 2021 Filed Jan 8, 2021 00:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 4,751 | $58.09 | $275,985.59 |
DisclosureSEC source: 0001209191-21-002618 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.87 to 58.5, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.